NASDAQ$PRME
Prime Medicine Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Prime Medicine reported full year 2023 financial results and provided business updates, maturing into a clinical-stage company.
Prime Medicine reported its full year 2023 financial results, highlighting its progress in advancing its Prime Editing platform and therapeutic programs. The company is on track to file an IND application or CTA for PM359 in the first half of 2024, with initial data expected in 2025. Additionally, Prime Medicine completed an upsized $161 million public offering.
- On track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025.
- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024.
- Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation.
- Completed upsized $161 million public offering.
Headline financials
Revenue & EPS history
Prime Medicine · Revenue · Quarterly
$0
Forward guidance
Prime Medicine anticipates undergoing a significant transformation in 2024, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients. The company expects several activities and next steps to drive its progress, including advancing programs into lead optimization, initiating IND-enabling activities, and establishing delivery platforms.
Tailwinds
- Open investigational new drug (IND) application and/or clinical trial application (CTA) for Phase 1/2 study in CGD in the first half of 2024, with initial clinical data anticipated in 2025.
- Advance Shielded Hematopoietic Stem Cell (HSC) and Immunotherapy Pairs (SCIP) technology, establish proof-of-concept in HSC and immunotherapy and identify first clinical program(s) with this approach in 2024.
- Advance differentiated CAR-T program, using PASSIGE technology, into lead optimization.
- Continue to advance preclinical studies for three liver programs and initiate IND-enabling activities for at least one in 2024, leading to an IND and/or CTA in the second half of 2025 or first half of 2026.
- Nominate development candidate for Retinitis Pigmentosa/Rhodopsin (RHO) and initiate IND-enabling activities in 2024.
Headwinds
- Uncertainties related to an IND or CTA filing and entering clinical trials.
- Risks related to the development and optimization of new technologies.
- The results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies.
- The scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology.
- General economic, industry and market conditions, including rising interest rates, inflation, and adverse developments affecting the financial services industry.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2023
-1.7%
Avg return
Earnings day
-7.2%
Avg return
5 days after
-10.8%
Avg return
30 days after
29%
5 / 17 earnings
Positive
+26.6%
Q1 2025
Best reaction
-9.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -8.2% | -13.9% | -28.8% | |
| Q3 2025 | -9.1% | -15.1% | -10.5% | |
| Q1 2025 | +26.6% | -7.5% | +15.9% | |
| Q4 2024 | +4.1% | -4.5% | -17.8% | |
| Q3 2024 | -9.8% | -23.8% | -31.4% | |
| Q2 2024 | -4.5% | -2.5% | -19.3% | |
| Q1 2024 | +12.2% | +18.2% | +14.9% | |
| Q4 2023 | +1.6% | -2.4% | -18.9% | |
| Q3 2023 | +17.0% | +13.1% | +21.6% | |
| Q2 2023 | -7.5% | -14.9% | -13.3% | |
| Q1 2022 | -9.4% | -10.5% | +3.2% | |
| Q1 2023 | -9.4% | -10.5% | +3.2% | |
| Q4 2020 | -9.7% | -11.7% | -21.9% | |
| Q4 2022 | -9.7% | -11.7% | -21.9% | |
| Q3 2022 | -4.4% | -8.1% | -19.4% | |
| Q3 2021 | -4.4% | -8.1% | -19.4% | |
| Q4 2021 | -4.4% | -8.1% | -19.4% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro